Soluble beta amyloid evokes alteration in brain norepinephrine levels: Role of nitric oxide and interleukin-1

Frontiers in Neuroscience

Volumn 9, Issue NOV, 2015, Pages

  Morgese, Maria G ^a   Colaianna, Marilena ^a,b   Mhillaj, Emanuela ^a,c   Zotti, Margherita ^a   Schiavone, Stefania ^a   D'Antonio, Palma ^a   Harkin, Andrew ^d   Gigliucci, Valentina ^d   Campolongo, Patrizia ^c   Trezza, Viviana ^e   De Stradis, Angelo ^f   Tucci, Paolo ^a   Cuomo, Vincenzo ^c   Trabace, Luigia ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e ROMA TRE UNIVERSITY   (Italy)

^f INSTITUTE FOR SUSTAINABLE PLANT PROTECTION   (Italy)

Author keywords

Hippocampus; Interleukin 1; Nitric oxide; Norepinephrine; Nucleus accumbens; Prefrontal cortex; Soluble beta amyloid

Indexed keywords

7 NITROINDAZOLE; AMYLOID BETA PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN BRAIN LEVEL; PHARMACOLOGICAL PROCEDURES; RAT;

EID: 84949568592     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00428     Document Type: Article

References (59)

1. Austin, S. A., d'Uscio, L. V., and Katusic, Z. S. (2013). Supplementation of nitric oxide attenuates AbetaPP and BACE1 protein in cerebral microcirculation of eNOS-deficient mice. J. Alzheimers Dis. 33, 29-33. doi: 10.3233/JAD-2012-121351.
2. Austin, S. A., Santhanam, A. V., and Katusic, Z. S. (2010). Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ. Res. 107, 1498-1502. doi: 10.1161/CIRCRESAHA.110.233080.
3. Béchade, C., Pascual, O., Triller, A., and Bessis, A. (2011). Nitric oxide regulates astrocyte maturation in the hippocampus: involvement of NOS2. Mol. Cell. Neurosci. 46, 762-769. doi: 10.1016/j.mcn.2011.02.009.
4. Braun, D., Madrigal, J. L., and Feinstein, D. L. (2014). Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications. Curr. Neuropharmacol. 12, 342-352. doi: 10.2174/1570159X12666140828220938.
5. Chakroborty, S., Kim, J., Schneider, C., West, A. R., and Stutzmann, G. E. (2015). Nitric oxide signaling is recruited as a compensatory mechanism for sustaining synaptic plasticity in Alzheimer's disease mice. J. Neurosci. 35, 6893-6902. doi: 10.1523/JNEUROSCI.4002-14.2015.
6. Chen, M. J., Ivy, A. S., and Russo-Neustadt, A. A. (2006). Nitric oxide synthesis is required for exercise-induced increases in hippocampal BDNF and phosphatidylinositol 3' kinase expression. Brain Res. Bull. 68, 257-268. doi: 10.1016/j.brainresbull.2005.08.013.
7. Chen, M. J., and Russo-Neustadt, A. A. (2005). Exercise activates the phosphatidylinositol 3-kinase pathway. Brain Res. Mol. Brain Res. 135, 181-193. doi: 10.1016/j.molbrainres.2004.12.001.
8. Chen, M. J., and Russo-Neustadt, A. A. (2007). Nitric oxide signaling participates in norepinephrine-induced activity of neuronal intracellular survival pathways. Life Sci. 81, 1280-1290. doi: 10.1016/j.lfs.2007.09.003.
9. Choi, D. Y., Liu, M., Hunter, R. L., Cass, W. A., Pandya, J. D., Sullivan, P. G., et al. (2009). Striatal neuroinflammation promotes Parkinsonism in rats. PLoS ONE 4:e5482. doi: 10.1371/journal.pone.0005482.
10. Colaianna, M., Tucci, P., Zotti, M., Morgese, M. G., Schiavone, S., Govoni, S., et al. (2010). Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state? Br. J. Pharmacol. 159, 1704-1715. doi: 10.1111/j.1476-5381.2010.00669.x.
11. Contestabile, A., and Ciani, E. (2004). Role of nitric oxide in the regulation of neuronal proliferation, survival and differentiation. Neurochem. Int. 45, 903-914. doi: 10.1016/j.neuint.2004.03.021.
12. Counts, S. E., and Mufson, E. J. (2010). Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J. Neurochem. 113, 649-660. doi: 10.1111/j.1471-4159.2010.06622.x.
13. Dello Russo, C., Boullerne, A. I., Gavrilyuk, V., and Feinstein, D. L. (2004). Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J. Neuroinflammation 1:9. doi: 10.1186/1742-2094-1-9.
14. Di Carlo, M., Giacomazza, D., and San Biagio, P. L. (2012). Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. J. Phys. Condens. Matter 24:244102. doi: 10.1088/0953-8984/24/24/244102.
15. Feinstein, D. L., Galea, E., and Reis, D. J. (1993). Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J. Neurochem. 60, 1945-1948. doi: 10.1111/j.1471-4159.1993.tb13425.x.
16. Feinstein, D. L., Heneka, M. T., Gavrilyuk, V., Dello Russo, C., Weinberg, G., and Galea, E. (2002). Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 41, 357-365. doi: 10.1016/S0197-0186(02)00049-9.
17. Fernandez, A. P., Pozo-Rodrigalvarez, A., Serrano, J., and Martinez-Murillo, R. (2010). Nitric oxide: target for therapeutic strategies in Alzheimer's disease. Curr. Pharm. Des. 16, 2837-2850. doi: 10.2174/138161210793176590.
18. Garthwaite, J. (1991). Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 14, 60-67. doi: 10.1016/0166-2236(91)90022-M.
19. Gentile, M. T., Vecchione, C., Maffei, A., Aretini, A., Marino, G., Poulet, R., et al. (2004). Mechanisms of soluble beta-amyloid impairment of endothelial function. J. Biol. Chem. 279, 48135-48142. doi: 10.1074/jbc. M407358200.
20. Grange-Messent, V., Raison, D., Dugas, B., and Calas, A. (2004). Noradrenaline up-regulates the neuronal and the inducible nitric oxide synthase isoforms in magnocellular neurons of rat brain slices. J. Neurosci. Res. 78, 683-690. doi: 10.1002/jnr.20331.
21. Grilli, M., Lagomarsino, F., Zappettini, S., Preda, S., Mura, E., Govoni, S., et al. (2010). Specific inhibitory effect of amyloid-beta on presynaptic muscarinic receptor subtypes modulating neurotransmitter release in the rat nucleus accumbens. Neuroscience 167, 482-489. doi: 10.1016/j.neuroscience.2010.01.058.
22. Guix, F. X., Uribesalgo, I., Coma, M., and Muñoz, F. J. (2005). The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76, 126-152. doi: 10.1016/j.pneurobio.2005.06.001.
23. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi: 10.1126/science.1072994.
24. Heneka, M. T., Galea, E., Gavriluyk, V., Dumitrescu-Ozimek, L., Daeschner, J., O'Banion, M. K., et al. (2002). Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22, 2434-2442. doi: 10.1136/jnnp.2005.075358.
25. Heneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., et al. (2010). Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U.S.A. 107, 6058-6063. doi: 10.1073/pnas.0909586107.
26. Hsieh, C. H., Li, H. Y., and Chen, J. C. (2010). Nitric oxide and interleukin-1beta mediate noradrenergic induced corticotrophin-releasing hormone release in organotypic cultures of rat paraventricular nucleus. Neuroscience 165, 1191-1202. doi: 10.1016/j.neuroscience.2009.12.003.
27. Iammarino, M., Di Taranto, A., and Muscarella, M. (2012). Investigation on the presence of sulphites in fresh meat preparations: estimation of an allowable maximum limit. Meat Sci. 90, 304-308. doi: 10.1016/j.meatsci.2011.07.015.
28. Igbavboa, U., Johnson-Anuna, L. N., Rossello, X., Butterick, T. A., Sun, G. Y., and Wood, W. G. (2006). Amyloid beta-protein1-42 increases cAMP and apolipoprotein E levels which are inhibited by beta1 and beta2-adrenergic receptor antagonists in mouse primary astrocytes. Neuroscience 142, 655-660. doi: 10.1016/j.neuroscience.2006.06.056.
29. Kalinin, S., Polak, P. E., Madrigal, J. L., Gavrilyuk, V., Sharp, A., Chauhan, N., et al. (2006). Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist. Antioxid. Redox Signal. 8, 873-883. doi: 10.1089/ars.2006.8.873.
30. Kamikawa, H., Hori, T., Nakane, H., Aou, S., and Tashiro, N. (1998). IL-1beta increases norepinephrine level in rat frontal cortex: involvement of prostanoids, NO, and glutamate. Am. J. Physiol. 275, R803-R810.
31. Kar, S., Slowikowski, S. P., Westaway, D., and Mount, H. T. (2004). Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J. Psychiatry Neurosci. 29, 427-441.
32. Kong, Y., Ruan, L., Qian, L., Liu, X., and Le, Y. (2010). Norepinephrine promotes microglia to uptake and degrade amyloid beta peptide through upregulation of mouse formyl peptide receptor 2 and induction of insulin-degrading enzyme. J. Neurosci. 30, 11848-11857. doi: 10.1523/JNEUROSCI.2985-10.2010.
33. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., et al. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95, 6448-6453. doi: 10.1073/pnas.95.11.6448.
34. Liu, X., Ye, K., and Weinshenker, D. (2015). Norepinephrine protects against amyloid-beta toxicity via TrkB. J. Alzheimers. Dis. 44, 251-260. doi: 10.3233/JAD-141062.
35. Lonart, G., Wang, J., and Johnson, K. M. (1992). Nitric oxide induces neurotransmitter release from hippocampal slices. Eur. J. Pharmacol. 220, 271-272. doi: 10.1016/0014-2999(92)90759-W.
36. Meffert, M. K., Calakos, N. C., Scheller, R. H., and Schulman, H. (1996). Nitric oxide modulates synaptic vesicle docking fusion reactions. Neuron 16, 1229-1236. doi: 10.1016/S0896-6273(00)80149-X.
37. Miller, T. W., Isenberg, J. S., Shih, H. B., Wang, Y., and Roberts, D. D. (2010). Amyloid-beta inhibits No-cGMP signaling in a CD36-and CD47-dependent manner. PLoS ONE 5:e15686. doi: 10.1371/journal.pone.0015686.
38. Moncada, S., Palmer, R. M., and Higgs, E. A. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109-142.
39. Morgese, M. G., Tucci, P., Colaianna, M., Zotti, M., Cuomo, V., Schiavone, S., et al. (2014). Modulatory activity of soluble beta amyloid on HPA axis function in rats. Curr. Pharm. Des. 20, 2539-2546. doi: 10.2174/13816128113199990500.
40. Mura, E., Lanni, C., Preda, S., Pistoia, F., Sarà, M., Racchi, M., et al. (2010a). Beta-amyloid: a disease target or a synaptic regulator affecting age-related neurotransmitter changes? Curr. Pharm. Des. 16, 672-683. doi: 10.2174/138161210790883723.
41. Mura, E., Preda, S., Govoni, S., Lanni, C., Trabace, L., Grilli, M., et al. (2010b). Specific neuromodulatory actions of amyloid-beta on dopamine release in rat nucleus accumbens and caudate putamen. J. Alzheimers. Dis. 19, 1041-1053. doi: 10.3233/JAD-2010-1299.
42. Mura, E., Zappettini, S., Preda, S., Biundo, F., Lanni, C., Grilli, M., et al. (2012). Dual effect of beta-amyloid on alpha7 and alpha4beta2 nicotinic receptors controlling the release of glutamate, aspartate and GABA in rat hippocampus. PLoS ONE 7:e29661. doi: 10.1371/journal.pone.0029661.
43. Murad, F. (2003). The excitement and rewards of research with our discovery of some of the biological effects of nitric oxide. Circ. Res. 92, 339-341. doi: 10.1161/01.RES.0000061772.73917.99.
44. Palumbo, M. L., Fosser, N. S., Rios, H., Zorrilla Zubilete, M. A., Guelman, L. R., Cremaschi, G. A., et al. (2007). Loss of hippocampal neuronal nitric oxide synthase contributes to the stress-related deficit in learning and memory. J. Neurochem. 102, 261-274. doi: 10.1111/j.1471-4159.2007.04528.x.
45. Patel, N. J., Chen, M. J., and Russo-Neustadt, A. A. (2010). Norepinephrine and nitric oxide promote cell survival signaling in hippocampal neurons. Eur. J. Pharmacol. 633, 1-9. doi: 10.1016/j.ejphar.2010.01.012.
46. Paxinos, G., and Watson, C. (1998). The Rat Brain in Stereotaxic Coordinates. New York, NY: Elsevier Academic Press.
47. Preda, S., Govoni, S., Lanni, C., Racchi, M., Mura, E., Grilli, M., et al. (2008). Acute beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology 33, 1062-1070. doi: 10.1038/sj.npp.1301485.
48. Puzzo, D., Palmeri, A., and Arancio, O. (2006). Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease. Rev. Neurosci. 17, 497-523. doi: 10.1515/REVNEURO.2006.17.5.497.
49. Puzzo, D., Vitolo, O., Trinchese, F., Jacob, J. P., Palmeri, A., and Arancio, O. (2005). Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci. 25, 6887-6897. doi: 10.1523/JNEUROSCI.5291-04.2005.
50. Russell, C. L., Semerdjieva, S., Empson, R. M., Austen, B. M., Beesley, P. W., and Alifragis, P. (2012). Amyloid-beta acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. PLoS ONE 7:e43201. doi: 10.1371/journal.pone.0043201.
51. Sanz, J. M., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., et al. (2009). Activation of microglia by amyloid β requires P2X7 receptor expression. J. Immunol. 182, 4378-4385. doi: 10.4049/jimmunol.0803612.
52. Saulskaya, N. B., Fofonova, N. V., and Sudorgina, P. V. (2010). Activation of the NO-ergic system of the nucleus accumbens on presentation of contextual danger signals. Neurosci. Behav. Physiol. 40, 907-912. doi: 10.1007/s11055-010-9344-y.
53. Snyder, S. H., and Bredt, D. S. (1991). Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci. 12, 125-128. doi: 10.1016/0165-6147(91)90526-X.
54. Taepavarapruk, P., and Song, C. (2010). Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1beta administrations: effects of omega-3 fatty acid EPA treatment. J. Neurochem. 112, 1054-1064. doi: 10.1111/j.1471-4159.2009.06524.x.
55. Trabace, L., Cassano, T., Tucci, P., Steardo, L., Kendrick, K. M., and Cuomo, V. (2004). The effects of nitric oxide on striatal serotoninergic transmission involve multiple targets: an in vivo microdialysis study in the awake rat. Brain Res. 1008, 293-298. doi: 10.1016/j.brainres.2004.01.090.
56. Trabace, L., Kendrick, K. M., Castrignanò, S., Colaianna, M., De Giorgi, A., Schiavone, S., et al. (2007). Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. Neuroscience 147, 652-663. doi: 10.1016/j.neuroscience.2007.04.056.
57. Trabace, L., Zotti, M., Morgese, M. G., Tucci, P., Colaianna, M., Schiavone, S., et al. (2011). Estrous cycle affects the neurochemical and neurobehavioral profile of carvacrol-treated female rats. Toxicol. Appl. Pharmacol. 255, 169-175. doi: 10.1016/j.taap.2011.06.011.
58. Tucci, P., Mhillaj, E., Morgese, M. G., Colaianna, M., Zotti, M., Schiavone, S., et al. (2014). Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. Front. Behav. Neurosci. 8:332. doi: 10.3389/fnbeh.2014.00332.
59. Wang, D., Yuen, E. Y., Zhou, Y., Yan, Z., and Xiang, Y. K. (2011). Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons. J. Biol. Chem. 286, 31852-31863. doi: 10.1074/jbc. M111.244335.